Journals / Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2015 / Cilt: 26 - Sayı: 2

Correlation Between Sex Hormones, SHBG Levels, and Insulin Resistance in Premenopausal and Postmenopausal Obese Women

Premenopozal ve Postmenopozal Obez Kadınlarda Seks Hormonları, SHBG Düzeyi ve İnsülin Direnci Arasında İlişki

Pages
132–138
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Although other studies suggested that SHBG isa marker of insulin resistance, our results do not confirm thisassociation between SHBG and HOMA-IR in obese women.Further studies with more subj ects are required to explore thisissue.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Sex hormones are closely related to regulation ofadiposity.
📊
Key Findings & Data:Patients who were di- agnosed with diabetes mellitus (DM) or polycystic ovary syn- drome (PCOS), having a history of chronic liver disease, havingthyroid or renal dysfunction, or taking any medication knownto interfere with glucose and insulin secretion were excluded.Subj ects were divided into 2 groups: premenopausal (n=3 1)and postmenopausal (n=35).
💡
Conclusion & Impact:Conclusion: Although other studies suggested that SHBG isa marker of insulin resistance, our results do not confirm thisassociation between SHBG and HOMA-IR in obese women.Further studies with more subj ects are required to explore thisissue.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Sex hormones are closely related to regulation ofadiposity. Sex hormone-binding globulin (SHBG) is the primaryplasma transport protein for sex steroids, and it is responsiblefor their biologic activities. Previous studies suggested thatSHBG is a marker for insulin resistance. In this study, we aimedto determine the relationship between SHBG and homeostasismodel assessment of insulin resistance (HOMA-IR) in pre- andpostmenopausal obese women. Methods: Six ty-six obese women who were attending anobesity outpatient clinic were enrolled. Patients who were di- agnosed with diabetes mellitus (DM) or polycystic ovary syn- drome (PCOS), having a history of chronic liver disease, havingthyroid or renal dysfunction, or taking any medication knownto interfere with glucose and insulin secretion were excluded.Subj ects were divided into 2 groups: premenopausal (n=3 1)and postmenopausal (n=35). All patients completed a ques- tionnaire which included sociodemographic characteristics.Sex hormones, SHBG, and HOMA-IR were measured. Results: In the pre- and postmenopausal groups, mean agewas 37.3±7.6 years and 56.2±6.5 years, respectively. Meanbody mass index (BMI) was similar in both groups (38.4±6 kg/ m2, 37.8±5.5 kg/m2, respectively). Postmenopausal womenhad lower SHBG levels than premenopausal (38.6± 15.4 nmol/L,-44.4± 17. 1 nmol/L, respectively, p=0. 1). No correlation wasfound between SHBG concentrations and insulin resistancecalculated by HOMA index. Conclusion: Although other studies suggested that SHBG isa marker of insulin resistance, our results do not confirm thisassociation between SHBG and HOMA-IR in obese women.Further studies with more subj ects are required to explore thisissue.

Özet

Amaç: Seks hormonları vücuttaki yağ dağılımının düzenlen- mesi ile yakından ilişkilidir. Seks hormon bağlayıcı globülin(SHBG), seks steroidlerinin primer plazma transport proteini- dir ve seks hormonlarının biyolojik aktivitelerini düzenlemek- le sorumludur. Önceki çalışmalar SHBGnin insülin direnci içinbir belirteç olduğu ileri sürülmüştür. Bu yazıda, obez preme- napozal ve postmenopozal kadınlarda SHBG kan düzeyleriile insülin direnci arasındaki ilişkiyi göstermeyi amaçladık. Gereç ve Yöntem: Çalışmaya obezite polikliniğine başvuranardışık 66 obez kadın alındı. Hastaların demografik özellik- leri ve klinik bilgileri sorgulandı. Hastalardan diyabet tanısıolan, glukoz metabolizmasını etkileyen herhangi bir ilaçkullanan, polikistik over sendromu gibi hiperandrojeniminineşlik edebileceği hastalık, tiroid fonksiyon bozukluğu, renalfonksiyon bozukluğu ve kronik karaciğer parankimal hasta- lık öyküsü olanlar dışlandı. Hastalar premenapozal (n=31) vepostmenapozal (n=35) olmak üzere iki gruba ayrıldı. Endo- jen seks hormonları, SHBG ve HOMA-IR değerlendirildi. Bulgular: Pre ve postmenapozal grupta sırasıyla ortalama yaş37.3±7.6 yıl-56.2±6.5 yıl olarak saptandı. Ortalama vücut kitleindeksi (VKİ) her iki grupta benzer bulundu (sırasıyla, 38.4±6kg/m2 ve 37.8±5.5 kg/m2). Postmenapozal kadınlar premena- pozal olanlara göre daha düşük SHBG düzeyine sahip olmaklabirlikte anlamlı değildi (sırasıyla, 38.6±15.4 nmol/L -44.4±17.1nmol/L p=0.1). SHBG düzeyi ve HOMA indeksi ile hesaplananinsulin direnci arasında ilişki bulunamadı. Sonuç: Önceki çalışmalarda SHBG insülin direncini gösterme- de önemli bir belirteç olarak belirtilsede çalışmamızda hempre hem postmenopozal kadınlarda HOMA-IR ile SHBG ara- sında anlamlı ilişki tespit edemedik. SHBGnin insülin direncinigöstermede bir belirteç olup olmayacağını gösterecek dahafazla hasta katılımıyla yapılacak çalışmalara ihtiyaç vardır.

🔖

Cite This Article

TEKİN, S., TEMİZKAN, Ş., MENKE, M., KAPTANAĞASI, A., KARABAYRAKTAR, T., TEKİN, B., SARGIN, M. (2022). Correlation Between Sex Hormones, SHBG Levels, and Insulin Resistance in Premenopausal and Postmenopausal Obese Women. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 26 - Sayı: 2, 132–138. https://ajindex.com/articles/571300

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Fram- ingham study. Ann Intern Med 1976;85(4):447–52
  2. Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 2002;5(2):27–37
  3. Lejsková M, Alušík S, Valenta Z, Adámková S, Piťha J. Natural postmenopause is associated with an increase in combined cardiovascular risk factors. Physiol Res 2012;61(6):587–96
  4. Tchernof A, Calles-Escandon J, Sites CK, Poehlman ET. Menopause, central body fatness, and insulin resistance: effects of hormone-replacement therapy. Coron Artery Dis 1998;9(8):503–11
  5. Hoover LW, Boote EJ. Longitudinal assessment of intra- abdominal fat in postmenopausal women. Ann N Y Acad Sci 2000;904:520–5
  6. Maggio M, Ceda GP, Lauretani F, Bandinelli S, Corsi AM, Giallauria F, et al. SHBG, sex hormones, and inflamma- tory markers in older women. J Clin Endocrinol Metab 2011;96(4):1053–9
  7. Jouyandeh Z, Nayebzadeh F, Qorbani M, Asadi M. Meta- bolic syndrome and menopause. J Diabetes Metab Dis- ord 2013;12(1):1
  8. Cho GJ, Lee JH, Park HT, Shin JH, Hong SC, Kim T, et al. Postmenopausal status according to years since meno- pause as an independent risk factor for the metabolic syndrome. Menopause 2008;15(3):524–9
  9. Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas 2010;65(3):262–6
  10. Ding EL, Song Y, Manson JE, Rifai N, Buring JE, Liu S. Plas- ma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia 2007;50(10):2076–84
  11. Golden SH, Dobs AS, Vaidya D, Szklo M, Gapstur S, Kopp P, et al. Endogenous sex hormones and glucose toler- ance status in postmenopausal women. J Clin Endocri- nol Metab 2007;92(4):1289–95
  12. Kalyani RR, Franco M, Dobs AS, Ouyang P, Vaidya D, Ber- toni A, et al. The association of endogenous sex hor- mones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab 2009;94(11):4127–35
  13. Bonnet F, Balkau B, Malécot JM, Picard P, Lange C, Fum- eron F, et al. Sex hormone-binding globulin predicts the incidence of hyperglycemia in women: interactions with adiponectin levels. Eur J Endocrinol 2009;161(1):81–5
  14. Heald AH, Anderson SG, Ivison F, Riste L, Laing I, Cruick- shank JK, et al. Low sex hormone binding globulin is a potential marker for the metabolic synd